To assess the prevalence and frequency of haematological testing in patients on clozapine.
Approach:
Study Design: A cohort study using three US health insurance claims databases from January 2000 to March 2022.
Testing Assessment: Evaluated the proportion of individuals with at least one haematological test prior to clozapine initiation and the frequency of testing during specified follow-up periods.
Hematological testing was completed prior to clozapine initiation and during the first 6 months of treatment, but was in accordance with testing requirements thereafter.
Limitations:
Limited understanding of reasons for less-than-recommended testing frequency.
Potential underreporting of testing due to reliance on billing codes.
Conclusion:
Routine haematological testing may not consistently occur despite recommendations, warranting further investigation into adherence.
by Katsiaryna Bykov, Mufaddal Mahesri, Krista F Huybrechts, Lauren V Moran, Catherine S Hwang, Junyi Wang, Joyce Lii, Gita A Toyserkani, Esther H Zhou, Cynthia LaCivita, Gerald J Dal Pan, Aaron S Kesselheim, Ameet Sarpatwari
